Forgot your password?

Forgot your username?

OXiGENE Biotech Specialty Pharma

701 Gateway Blvd, Suite 210
South San Francisco, CA 94080 USA
Click for website
Research Sector Biotech Specialty Pharma
Summary Description Therapeutics: Cancer, sight-threatening illnesses

Click here for Financial Data Keywordsfosbretabulin, anaplastic, randomized, chemotherapeutic, bevacizumab, cancer, oncology, ovarian cancer, ophthalmology


OXiGENE is a biopharmaceutical company whose mission is finding (via discovery or in-licensing) and developing new and improved therapeutics that deliver significant medical benefits to patients with ......view more

Products / Services

The lead compound in clinical development is ZYBRESTAT?, a potential treatment for ovarian and certain thyroid cancers. VDAs are a new and highly differentiated class of anti-vascular drug that target......view more

Technology / Differentiation

Vascular disruption is a new approach to a validated therapeutic strategy: depriving tumors and, in the case of eye disease, pathologic neovascular lesions, of blood supply....view more

Market / Customers

OXiGENE is focused on developing innovative new therapies for cancer that address serious unmet needs. The company is working on treatments for serious diseases such as ovarian cancer, a highly lethal......view more


OXiGENE's lead VTA, Combretastatin A4 Prodrug, has advanced into Phase II and combination clinical trials in cancer patients in the United States and Europe. The investigational compound also is being...view more